SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.

Slides:

Advertisements

Similar presentations

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Advertisements

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

HCV Assays: Impact on HCV Studies & Update on HCV blood bank protocol.

Dr. Thaweesak Tirawatnapong Chula Medical Research Center (Chula MRC)

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

The Sense of Sensitivity I Dr. Matthias Gessner Plasma Control Europe/Plasma Analytics Baxter AG, Vienna.

PCS Conference Reducing Inhibition of RT-PCR in plasma samples from cadavers Dr Simon Carne National Transfusion Microbiology Reference Laboratory (NTMRL)

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.

Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:

F. Kourgia, M. Vini, E. Zervou

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.

Plant virus infections induce tremendous economic losses for agricultural production each year in the U.S. Accurate and reliable diagnosis of the pathogens.

HIV Testing CDC power point edited by M. Myers

R Diagnostics June 19, 2003 WNV FDA BPAC MeetingPCR NAT Blood Screening TaqScreen West Nile Virus Program - Roche Update James L. Gallarda, Ph.D. Roche.

TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

Limitations of HBsAg testing in the screening of blood donors Wolfram H. Gerlich Institute of Medical Virology University Giessen, Germany SoGAT XVI Langen.

Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.

BioLife Plasma Services Experience with HBV NAT Testing

HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.

And the order changeth …. Evolving protocols for TTI testing

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.

Transmissibility of B19 by transfusion: evaluation of donor viremia prior to performing a linked donor-recipient study M Busch, representing REDS-II Parvo.

SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-

E A 1 Parvovirus B19 and HAV Screening of Whole Blood Donations SL Stramer, KL Kane, ML Beyers, RY Dodd, American Red Cross and RIF Smith, National.

Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.

Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.

Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.

Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.

NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.

SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,

Monitoring the Performance of Nucleic Acid Tests using Data Generated from EDCNet and DigitalPT Wayne Dimech, Darren Jardine, Thu-Anh Pham and the staff.

1 Procleix ® WNV Assay: A TMA-based Assay for Screening Blood Donations for West Nile Virus RNA Jeff Linnen, Ph.D. Research and Development Gen-Probe Incorporated,

Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.

SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,

Anti-B19 screening for safe cellular blood products for at–risk patients SoGAT XVIII, USA, May 24-25th, 2005 Harry Bos on behalf of Project Group Parvo.

W W W. Q I A G E N. C O M Dirk Heckel, PhD Diagnostic Sample Preparation and Stabilization QIAGEN GmbH.

Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.

Performance of Chiron Quantitative and Qualitative HBV PCR Assay and Confirmation of HBV Yield Cases Yiu-Lian Fong, Ph.D, Associate Director June 13, 2007.

A multi-centre NAT evaluation study of run and trend control samples Harry van Drimmelen 1, Joe O’Donnellan 2, Rene Bax 1, Henrik Ullum 3 and the Danish.

NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.

Elisa Moretti Process and Analytical Development KEDRION S.p.A SoGAT XVI Paul Ehrlich Institut - Langen, Germany 3 rd July 2003 Automated Extraction for.

Ro / BSD Hessen Institut für Transfusionsmedizin SoGAT XVII, Paris, Paris 2004 B19 Overview of Testing for Blood Banks W. Kurt Roth Red Cross Blood Transfusion.

DISCONTINUATION OR NO DISCONTIUNATION: COMPARISON OF SINGLE UNIT HIV ANTIGEN TESTING VS. POOLED NAT TESTING Gerald Schochetman, Ph.D. Abbott Laboratories.

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

DRK-Blutspendedienst West  nPrecipitation steps (PEG), centrifugation and careful resuspension of the invisible pelleted viral particles precede efficient.

DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large.

Risk assessment: The Safety of Blood Products presented by Dr. Thomas R. Kreil Baxter BioScience on behalf of the PPTA Pathogen Safety Steering Committee.

Quality Assessment for Blood Screening Laboratories in Australia and the Asian Pacific. Darren Jardine and Staff of the National Serology Reference Laboratory,

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.

 Routine viral diagnostics: indirect and direct detection of viruses. ◦ Indirect detection: serological tests; ◦ Direct detection:  Viral antigens;

Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.

Relative Sensitivities of US Licensed NAT Assays for Detection of Viremia in Early HIV and HCV Infection MP Busch, SA Glynn, DJ Wright, D Hirschkorn, ME.

NAME; BEDAN W KANGETHE BSC. BIOCHEMISTRY, NPHLS NHRL.

Saeko Mizusawa, Yoshiaki Okada

HCV by PCR Neelam Gajjar 7/26/2009.

Standardization of Sample Preparation for NAT

Longitudinal Quality Assurance of HIV Nucleic Acid Testing in Blood Screening D Jardine, S Best, EM Dax (National Serology Reference Laboratory, Australia)

Update on CBER HIV-1 Subtype panel

Evaluation data on the new Roche cobas s 201 system with the cobas TaqScreen MPX test Lutz Pichl, Volkmar Schottstedt German Red Cross Blood Transfusion.

Viral Safety of Blood Products in Taiwan

1st International Standard for HIV-1 RNA NIBSC Code 97/656

SoGAT meeting XXI May (2009), Brussels, Belgium

Challenges for Blood Donor Confirmatory Testing Algorithms

Presentation transcript:

SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz

SoGAT, Berne 2006BTS SRC Berne Ltd. NAT testing in progress HCV-PCRsince 01 ‘1999 HIV-1 PCRsince 03‘ 2002 increased blood safety automized test procedures

SoGAT, Berne 2006BTS SRC Berne Ltd. Procleix TIGRIS System fully automated NAT screening system combined detection of 3 viruses: HIV-1, HCV and HBV extraction/amplification/detection in one tube extraction based upon magnetic bead technology amplification based upon the TMA technology using RNA as amplified targed detection by chemiluminescence specific discrimination assays for virus identification

SoGAT, Berne 2006BTS SRC Berne Ltd. Design of the evalution study Assay validation: – sensitivity, specificity, robustness & cross-contamination Test performance under routine conditions – routine samples – pools of 8 or individual donations – pooling with Tecan pipetting robots – analysis with Procleix TIGRIS system

SoGAT, Berne 2006BTS SRC Berne Ltd. Sensitivity HIV-1:24.9 IU/ml (95 % C.I.: 20.2 – 33.3 IU/ml) ca copies/ml HCV: 3.7 IU/ml (95 % C.I.: 3.1 – 4.8 IU/ml) ca copies/ml HBV:7.6 IU/ml (95 % C.I.: 6.0 – 11.1 IU/ml) ca copies/ml

SoGAT, Berne 2006BTS SRC Berne Ltd. Robustness and reproducibility Procleix TIGRIS system: excellent robustness against cross-contamination reproducibility: intra-, inter-assay precision and between laboratories confirmed reliable test: 3 x 95% positive cut off value (HIV-1: 75 IU/ml, HCV: 11 IU/ml, HBV: 23 IU/ml) high robustness against inhibiting substances i.e. 100 I.U. heparin per sample no interference with lipaemic or haemolytic samples as a frequent donation related factor

SoGAT, Berne 2006BTS SRC Berne Ltd. Specificity – System Evaluation *) positive sample was a HBV window period donation

SoGAT, Berne 2006BTS SRC Berne Ltd. Summary very good test sensitivity, robustness and reliability clear discrimination between reactive and non reactive samples low level of invalid samples elevated level of „false“ positives with pools of 8 observed pool resolving requires more time and large sample quantities fully automated NAT screening system test and software easy to handle high throughput: single donation testing feasable very high degree of automatisation, but demanding hardware and little flexibility

SoGAT, Berne 2006BTS SRC Berne Ltd. Acknowledgments Christiane Schmidseder Rita Hubschmid Roger Hellmüller Dr. Christoph Niederhauser Dr. Philippe Schneider (BTS Lausanne) Chiron Corp.

SoGAT, Berne 2006BTS SRC Berne Ltd. Window period HBV donation identified by single donation testing donation already transfused at time of testing recipient developed a HBV viraemie 3 weeks post transfusion viral load of the initial donation not available, but… initial HBV titer must have been quite low: no longer detectable in a dilution of 1:8 and 1:24 101'621 IU/ml in 2 nd donation 35 days later